Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma T Bald, T Quast, J Landsberg, M Rogava, N Glodde, D Lopez-Ramos, ... Nature 507 (7490), 109-113, 2014 | 654 | 2014 |
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation J Landsberg, J Kohlmeyer, M Renn, T Bald, M Rogava, M Cron, M Fatho, ... Nature 490 (7420), 412-416, 2012 | 611 | 2012 |
A molecular single-cell lung atlas of lethal COVID-19 JC Melms, J Biermann, H Huang, Y Wang, A Nair, S Tagore, I Katsyv, ... Nature 595 (7865), 114-119, 2021 | 476 | 2021 |
A single-cell landscape of high-grade serous ovarian cancer B Izar, I Tirosh, EH Stover, I Wakiro, MS Cuoco, I Alter, C Rodman, ... Nature medicine 26 (8), 1271-1279, 2020 | 304 | 2020 |
Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy N Glodde, T Bald, D van den Boorn-Konijnenberg, K Nakamura, ... Immunity 47 (4), 789-802. e9, 2017 | 237 | 2017 |
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion CJ Frangieh, JC Melms, PI Thakore, KR Geiger-Schuller, P Ho, ... Nature genetics 53 (3), 332-341, 2021 | 140 | 2021 |
A stochastic model for immunotherapy of cancer M Baar, L Coquille, H Mayer, M Hölzel, M Rogava, T Tüting, A Bovier Scientific reports 6 (1), 24169, 2016 | 68 | 2016 |
Dissecting the treatment-naive ecosystem of human melanoma brain metastasis J Biermann, JC Melms, AD Amin, Y Wang, LA Caprio, A Karz, S Tagore, ... Cell 185 (14), 2591-2608. e30, 2022 | 62 | 2022 |
A preclinical model of malignant peripheral nerve sheath tumor-like melanoma is characterized by infiltrating mast cells M Hoelzel, J Landsberg, N Glodde, T Bald, M Rogava, S Riesenberg, ... Cancer research 76 (2), 251-263, 2016 | 35 | 2016 |
Inhibition of haspin kinase promotes cell-intrinsic and extrinsic antitumor activity JC Melms, S Vallabhaneni, CE Mills, C Yapp, JY Chen, E Morelli, ... Cancer research 80 (4), 798-810, 2020 | 25 | 2020 |
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity P Ho, JC Melms, M Rogava, CJ Frangieh, J Poźniak, SB Shah, Z Walsh, ... Cancer Cell 41 (7), 1207-1221. e12, 2023 | 16 | 2023 |
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators A Obradovic, C Ager, M Turunen, T Nirschl, M Khosravi-Maharlooei, ... Cancer cell 41 (5), 933-949. e11, 2023 | 15 | 2023 |
Tumor cell intrinsic Toll‐like receptor 4 signaling promotes melanoma progression and metastatic dissemination M Rogava, AD Braun, TC van der Sluis, N Shridhar, T Tüting, E Gaffal International Journal of Cancer 150 (1), 142-151, 2022 | 8 | 2022 |
The CD58: CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity P Ho, JC Melms, M Rogava, CJ Frangieh, SB Shah, Z Walsh, O Kyrysyuk, ... BioRxiv, 2022.03. 21.485049, 2022 | 6 | 2022 |
The myeloid cell type I IFN system promotes antitumor immunity over pro‐tumoral inflammation in cancer T‐cell therapy J Ruotsalainen, D Lopez‐Ramos, M Rogava, N Shridhar, N Glodde, ... Clinical & Translational Immunology 10 (4), e1276, 2021 | 6 | 2021 |
CXCR3: Here to stay to enhance cancer immunotherapy? M Rogava, B Izar EBioMedicine 49, 11-12, 2019 | 4 | 2019 |
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response CR Ager, M Zhang, M Chaimowitz, S Bansal, S Tagore, A Obradovic, ... Journal for Immunotherapy of Cancer 11 (9), 2023 | 3 | 2023 |
A stochastic individual-based model for immunotherapy of cancer M Baar, L Coquille, H Mayer, M Hölzel, M Rogava, T Tüting, A Bovier arXiv preprint arXiv:1505.00452, 2015 | 3 | 2015 |
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation M Rogava, TJ Aprati, WY Chi, JC Melms, C Hug, SH Davis, EM Earlie, ... Nature Cancer, 1-15, 2024 | 1 | 2024 |
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial NK Altorki, ZH Walsh, JC Melms, JL Port, BE Lee, A Nasar, C Spinelli, ... Nature Communications 14 (1), 8435, 2023 | 1 | 2023 |